Imatinib Axios (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, locking them in an inactive state. This blocks downstream signaling pathways that promote cell proliferation and survival, leading to apoptosis of malignant cells that rely on these kinases.

The specific dose and dosing schedule of Imatinib Axios are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal and hepatic function, and other individual factors. Patients should follow the exact regimen written on their prescription.

The safety of Imatinib Axios in pregnancy and lactation has not been fully established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and pregnancy planning with their healthcare provider.

To request Imatinib Axios, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine kinase inhibitor approved for CML and remains a standard first‑line option. Newer agents such as dasatinib and nilotinib have higher potency and may be used in cases of resistance or intolerance, but Imatinib’s long‑term safety profile and extensive clinical experience make it a widely accepted choice.

Imatinib Axios should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Imatinib Axios is taken orally, usually with a glass of water. It can be swallowed whole with or without food, unless the prescribing information advises otherwise. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

Serious adverse events include hepatotoxicity, severe neutropenia, cardiac failure, pulmonary hypertension, and rare but life‑threatening allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if they occur.

Imatinib Axios is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking medications that strongly interact with CYP3A4 without appropriate monitoring.